Brief: Sagimet Biosciences receives FDA nod to begin testing its therapy for acne
11/03/2025 13:38
March 11 (Reuters) - Sagimet Biosciences Inc SGMT.O: SAGIMET BIOSCIENCES ANNOUNCES CLEARANCE OF IND FOR FASN INHIBITOR TVB-3567, TO BE DEVELOPED FOR THE TREATMENT OF ACNE SAGIMET BIOSCIENCES INC - FIRST-IN-HUMAN PHASE 1 TRIAL OF TVB-3567 PLANNED IN 2025 Source text: nGNX50tVg7 Further company coverage: SGMT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage